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VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal
muscle troponin activator, as a potential treatment for patients with
amyotrophic lateral sclerosis: study design and baseline
characteristics
JINSY A. ANDREWS1, MERIT E. CUDKOWICZ2, ORLA HARDIMAN3, LISA MENG4,
AMY BIAN4, JACQUELINE LEE4, ANDREWA. WOLFF4, FADY I. MALIK4 & JEREMY
M. SHEFNER5
1Eleanor and Lou Gehrig ALS Center, Columbia University, New York, NY, USA, 2Department of Neurology,
Massachussetts General Hospital, Boston, MA, USA, 3Biomedical Sciences Institute of Neurosciences,
The University of Dublin, Dublin, Ireland, 4Cytokinetics, Inc, South San Francisco, CA, USA, and 5Department
of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA
Abstract
Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo on respiratory function
and other functional measures in patients with amyotrophic lateral sclerosis (ALS). This study was designed to confirm and
extend results from a large phase IIb trial and maximize tolerability with a slower dose escalation.Methods: VITALITY-ALS
(NCT02496767) was a multinational, double-blind, randomized, placebo-controlled, parallel-group study in ALS
patients. Participants who tolerated two weeks of open-label tirasemtiv (125mg twice a day) were randomized 3:2:2:2 to
placebo or one of three target total daily dose levels of tirasemtiv (250, 375, or 500mg). Participants randomized to
tirasemtiv escalated their dose every two weeks to their target dose level or maximum tolerated dose. The primary outcome
measure was change in slow vital capacity from baseline to 24 weeks. Secondary endpoints assessed the effect of tirasemtiv
on muscle strength and certain respiratory milestones of disease progression. A four-week randomized withdrawal phase
followed 48 weeks of treatment to evaluate the possibility of sustained benefit or rebound decline. Results: Data collection
will be complete in the fourth quarter of 2017. Conclusions: VITALITY-ALS was a phase III trial designed to evaluate the
efficacy, safety, and tolerability of tirasemtiv in ALS.
Keywords: Tirasemtiv, amyotrophic lateral sclerosis, slow vital capacity
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disorder characterized by the loss of
upper and lower motor neurons that leads to
progressive muscle weakness (1–3). Respiratory
muscle weakness often results in respiratory failure,
which is the most common cause of death in ALS
(4,5). Many patients die within 3–5 years after
diagnosis (6,7). Riluzole and edaravone are
approved in several countries as disease-modifying
therapy (8–10).
One approach to treating ALS is to directly
target the skeletal muscles (11). Tirasemtiv, a fast
skeletal muscle troponin activator (FSTA), increases
the contractile response of the sarcomere by select-
ively binding to the fast skeletal muscle troponin
complex, sensitizing the sarcomere to calcium by
slowing the rate of calcium ion release (12,13).
Tirasemtiv improved physical function in the SOD1
mouse model of ALS (12) and, in nerve-muscle
preparations, in vivo animal models, and healthy
human volunteers (14), amplified the force gener-
ated during submaximal nerve stimulation.
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In a large, multinational, randomized, double-
blind, placebo-controlled phase IIb study (Blinded
Evaluation of Neuromuscular Effects and
Functional Improvement with Tirasemtiv in ALS
(BENEFIT-ALS)) (15), 596 participants with ALS
(slow vital capacity (SVC)450% predicted) who
tolerated open-label tirasemtiv 125mg twice a day
(BID) for one week were randomized 1:1 to placebo
or tirasemtiv and received at least one dose of
double-blind therapy. Participants randomized to
tirasemtiv underwent dose escalation to a maximum
tolerated dose of 250mg BID in the 12-week
double-blind phase of the study. Those in the
tirasemtiv group taking riluzole received half their
riluzole dose (their evening dose was a matched
placebo), while participants in the placebo group
received the full dose of riluzole. This riluzole dose
reduction was included in the BENEFIT-ALS
design because previous studies showed that
tirasemtiv is a CYP1A2 inhibitor and when it is
administered with riluzole, tirasemtiv approximately
doubles riluzole exposure regardless of dose (7,16).
Although the primary endpoint (change from
baseline in ALS Functional Rating Scale-Revised
(ALSFRS-R)) did not show a significant treatment
effect in the BENEFIT-ALS study, SVC and muscle
strength declined significantly more slowly in
patients taking tirasemtiv (15). Tirasemtiv reduced
the slope of decline in SVC by approximately 50%
during the 12-week treatment phase (17). Significant
effects on the change from baseline in SVC were
observed at all doses reached (least squares mean
difference from placebo standard error: tirasemtiv
250mg, 7.14 2.10; tirasemtiv 375mg, 5.52 1.96;
tirasemtiv 500mg, 5.07 1.58; p¼ 0.0008, 0.0054,
and 0.0015, respectively) (17).
Clear conclusions regarding the lack of dose
dependency could not be reached because partici-
pants completed the trial on the above dose levels
based on tolerability rather than randomization (17).
Subgroup analyses showed that tirasemtiv reduced the
decline in SVC compared with placebo by a similar
magnitude regardless of riluzole use and that this
reduction was statistically significant at week 12
(tirasemtiv vs. placebo on riluzole: p50.005; tirasem-
tiv vs. placebo off riluzole: p50.0005) (17).
As seen during previous studies of tirasemtiv in
patients with ALS (7,16), dizziness was the most
commonly reported adverse event (AE) in
BENEFIT-ALS (15). Rates of dizziness were similar
in participants taking tirasemtiv regardless of
whether they were also taking riluzole (tirasemtiv +
riluzole: 49.5% [97/196]; tirasemtiv alone: 53.3%
[56/105]) (17). Furthermore, the duration of dizzi-
ness (mean and range) that began during the open-
label phase when all participants were receiving
tirasemtiv was similar regardless of whether the
participant transitioned to placebo or remained on
tirasemtiv during the double-blind randomized
phase of the study (18). This suggests that the
one-week open-label lead-in likely helped to prevent
dizziness from unblinding the double-blind treat-
ment randomization (18).
BENEFIT-ALS was the first clinical trial of its
size to demonstrate a positive and potentially clin-
ically meaningful effect on measures of respiratory
and skeletal muscle function in patients with ALS,
justifying the design and performance of a phase III
trial to evaluate the effect of tirasemtiv over a longer
duration of treatment. This trial was designed to
address specific questions raised by the results of
BENEFIT-ALS. As the relationship between dose
and clinical response was not clear, randomization
of participants to different target doses was imple-
mented in the phase III trial. In addition, because
many dropouts from tirasemtiv owing to AEs during
BENEFIT-ALS occurred shortly after randomiza-
tion and particularly after dose increases (15),
results suggested that a longer open-label phase
might succeed in better selecting participants who
would tolerate active treatment while a slower dose-
escalation schedule would reduce the risk of study
drug discontinuation. Therefore, the Ventilatory
Investigation of Tirasemtiv and Assessment of
Longitudinal Indices after Treatment for a Year
(VITALITY-ALS; NCT02496767) was designed
with modifications to address the above issues in
order to further assess the effect of tirasemtiv on
respiratory function in patients with ALS.
Patients and methods
Study design and participants
This multinational, double-blind, randomized, pla-
cebo-controlled, stratified, parallel-group study
enrolled adults with possible, probable, or definite
ALS in accordance with the revised El Escorial
criteria (19) from 79 sites in 11 countries (United
States, Canada, and Europe).
Participants were eligible for the study if they
had an upright SVC 70% of predicted for age,
height, and sex. Eligible participants were taking
riluzole at a stable dose (50mg BID for at least 30
days before screening) or were not taking riluzole.
Participants were able to swallow tablets without
crushing, and in the judgement of the site investi-
gators, would be able to swallow tablets for the
duration of the study. Additionally, eligible partici-
pants did not have any illness or laboratory
abnormalities that could confound the measurement
of ALS progression or interfere with their ability to
complete the study, and had not taken any investi-
gational study drug within 30 days of screening or
five half-lives of the prior agent before dosing. Prior
exposure to tirasemtiv was exclusionary, as was
pregnancy, and participants of both sexes were
required to use specific contraceptive measures.
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All participants in VITALITY-ALS provided writ-
ten informed consent for the study, and institutional
review board approvals were received at all sites before
enrollment. The study was conducted in accordance
with the Declaration of Helsinki. An independent data
and safety monitoring board monitored safety
throughout the study. This study was registered with
ClinicalTrials.gov (NCT02496767) and was funded
by Cytokinetics, Inc.
Study design
Following a screening period of no longer than 14
days, eligible participants were enrolled in the study.
VITALITY-ALS included three phases of treatment
with study drug (Figure 1): an open-label phase, a
double-blind, placebo-controlled phase, and a
double-blind, placebo-controlled tirasemtiv with-
drawal phase. A post-treatment follow-up period
followed completion of treatment with study drug.
The open-label period was extended from one week
in the BENEFIT-ALS study to two weeks in this
study to afford investigators and participants add-
itional time to consider whether any AEs the
participant might have experienced during the
open-label phase could be tolerated during a subse-
quent 48 weeks of double-blind therapy, which
might include an increase in the tirasemtiv dose.
Following completion of two weeks of treatment
with open-label tirasemtiv 125mg BID, participants
were randomized 3:2:2:2 to placebo and three differ-
ent target dose levels of tirasemtiv (250mg, 375mg,
or 500mg) stratified by riluzole use vs. nonuse (Table
1). Participants randomized to placebo received
tirasemtiv-matched placebo, while those randomized
to tirasemtiv target daily doses of 250mg, 375mg,
and 500mg received double-blind tirasemtiv for the
next 48 weeks. All participants on riluzole took 50mg
daily from their personal supply in the morning and a
blinded dose of riluzole in the evening in the same
manner as in BENEFIT-ALS. All participants rando-
mized to double-blind tirasemtiv continued at
250mg/day for the first two weeks of double-blind
treatment. Participants randomized to target daily
doses of 375mg or 500mg tirasemtiv had their doses
adjusted in 125mg increments every two weeks until
the target dose was reached or they experienced an
intolerable dose. Participants did not escalate their
dose if signs of intolerability were present and were
returned to a previously tolerated dose level if their
symptoms were believed to be due to treatment with
study drug. Decisions regarding dose escalation (or
not) and dose de-escalation occurred in a manner that
did not compromise blinding either to treatment or to
dose level. The blind was maintained by providing
prepacked daily doses of tirasemtiv and matching
placebo tablets during the double-blind phase of the
study such that a randomized patient would take two
tablets in the morning and two tablets in the evening
regardless of treatment or dose level. Therefore,
patients randomized to placebo would take two
placebo tablets twice daily, patients taking tirasemtiv
250mg total daily dose would take one 125mg
tirasemtiv tablet and one matching placebo tablet
twice daily, patients taking tirasemtiv 375mg total
daily dose would take one 125mg tirasemtiv tablet
and one matching placebo tablet in the morning and
two 125mg tirasemtiv tablets in the evening and
Option to
enter
open-label
extension
study 
Screening
tnemtaert fo dnErandomization ts1Enrollment
Placebo
Primary endpoint
assessment (week 24)
Screening
(2 weeks)
Open-label
(2 weeks)
Placebo-controlled phase
(48 weeks)
Withdrawal phase
(4 weeks)
Follow-up
(4 weeks)
Double-blind
2nd randomization
3
2
2
2
1
1
1
1
1
1
Open-label
250 mg/day
375 mg/day
Placebo
Current
dose
250 mg/day
Placebo
Current
dose
500 mg/day
Placebo
Current
dose
Figure 1. Study design.
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patients taking tirasemtiv 500mg total daily dose
would take two 125mg tirasemtiv tablets twice daily.
If the dose was increased or decreased, the patient
would be dispensed a new drug supply where they
would still take the same number of tablets per day
but would be provided a different tirasemtiv dose level
if they were randomized to treatment or they would
be provided placebo if they were randomized to the
placebo arm. This was done to allow for flexible
dosing to tolerability while blinding treatment and
dose level. Upon completion of the initial 48-week
double-blind, placebo-controlled phase, participants
receiving tirasemtiv were randomized a second time
1:1 to placebo or to continue their current active dose
level for four weeks of additional treatment as part of
the double-blind, placebo-controlled tirasemtiv with-
drawal phase; participants initially randomized to
placebo continued to receive placebo during this
phase of the trial.
Assessments
The primary endpoint was change in percent pre-
dicted SVC from baseline to week 24 of the double-
blind, placebo-controlled phase. Secondary end-
points assessed the effect of tirasemtiv on muscle
strength, the respiratory subscales of the ALSFRS-
R, and time to certain respiratory milestones of
disease progression, such as the initiation of assisted
ventilation during the 48 weeks of randomized
double-blinded treatment. Safety assessments
included physical examinations, clinical laboratory
evaluations, vital signs, AEs, and serious AE (SAEs)
monitoring. Banked samples for future biomarker
analysis were collected. A schedule of events is
shown in Table 2.
Statistical methods
The primary global null hypothesis was that there is
no treatment difference in the change from baseline
in percent predicted SVC at week 24 between
participants who had at least one post-dose SVC
measure and were randomized to placebo and those
randomized to tirasemtiv (pooled three target dose
levels) during the placebo-controlled, double-blind
treatment. It was calculated that approximately 360
participants needed to complete the 24 weeks of
double-blind treatment to provide 90% power to
detect a treatment difference from placebo in
percent predicted SVC change from baseline to
the end of the first 24-week phase of 6% for all
tirasemtiv target dose groups pooled with a common
standard deviation of 17% with a two-tailed alpha
error of 0.05. Assuming dropout rates at 24 weeks of
16% for placebo and 25% for all tirasemtiv target
dose groups combined, approximately 600 partici-
pants needed to be enrolled in the study and
approximately 477 participants needed to be rando-
mized to placebo and the three different target dose
levels of tirasemtiv in an allocation ratio of 3:2:2:2 in
the double-blind, placebo-controlled treatment
phase. To minimize the potential for missing data,
participants who discontinued study drug were
Table 1. Randomized double-blind treatment groups.
Group 1
(placebo)
Group 2
(target 250mg/day of
tirasemtiv)
Group 3
(target 375mg/day of
tirasemtiv)
Group 4
(target 500mg/day of
tirasemtiv)
Weeks 1–48
Two placebo tablets BID
Weeks 1–48
Morning: one tablet of tir-
asemtiv (125mg) + one
tablet of matching
placebo
Evening: one tablet
of tirasemtiv (125mg) + one
tablet of matching placebo
Weeks 1 and 2
Morning: one tablet
(125mg) of tirasemtiv+ one
tablet of matching placebo
Evening: one tablet of tir-
asemtiv (125mg) + one
tablet of matching placebo
Weeks 3–48
Morning: one tablet
(125mg) of tirasemtiv+ one
tablet of matching placebo
Evening: two tablets of tir-
asemtiv (250mg)
Weeks 1 and 2
Morning: one tablet
(125mg) of tirasemtiv+ one
tablet of matching placebo
Evening: one tablet of tir-
asemtiv (125mg) + one
tablet of matching placebo
Weeks 3 and 4
Morning: one tablet
(125mg) of tirasemtiv+ one
tablet of matching placebo
Evening: two tablets of
tirasemtiv (250mg)
Weeks 5–48
Morning: two tablets
(250mg) of tirasemtiv
Evening: two tablets of
tirasemtiv (250mg)
Riluzole users only
Group 1 (placebo) Groups 2–4 (active treatment groups)
Riluzole tablets
Morning: riluzole
(50mg; personal supply)
Evening: blinded
riluzole (50mg)
Riluzole tablets
Morning: riluzole (50mg; personal supply)
Evening: blinded riluzole-matched placebo
BID: twice a day.
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encouraged to perform all remaining study visits and
assessments for the duration of the study and most
importantly the assessments at Week 24. Unless
participants withdrew full consent for study partici-
pation, those participants who were unable to attend
scheduled future study visits were contacted by
phone on a monthly basis to obtain vital status and
respiratory status (i.e. use of noninvasive ventilation
or permanent mechanical ventilation) through 48
weeks.
Results
Baseline characteristics: open-label phase of the study
Of 866 participants screened, 744 were enrolled and
565 successfully completed the open-label phase
and were randomized. Of the 744 enrolled partici-
pants, the majority were men (65.2% [485/744]),
with an average age of 57.6 years and average SVC
of 90.7% predicted. Time to first symptom and time
to diagnosis were 20.6 months and 7.7 months,
respectively (Table 3). The majority of participants
(74.3% [553/744]) were taking riluzole at the start
of the study. Baseline characteristics between the
riluzole and non-riluzole strata were similar.
Safety and participant disposition
In the open-label phase of the study, 82.4% (613/
744) of participants experienced AEs, with dizziness
(44.4% [330/744]), fatigue (25.9% [193/744]), and
nausea (14.2% [106/744]) most common (Table 4).
Only 1.3% (10/744) of participants experienced
SAEs: three participants among those not taking
riluzole and seven participants among those taking
riluzole (Table 5).
During the open-label phase, 24.1% (179/744)
of participants discontinued of the study with
similar discontinuation rates seen in the participants
taking riluzole (23.3% [129/553) and participants
not taking riluzole (26.2% [50/191]) (Table 6). AEs
were the most common reason for discontinuation
with 10.3% (77/744) discontinuing because of
dizziness, 7.4% (55/744) because of fatigue, and
4.2% (31/744) because of nausea. Riluzole did not
significantly affect the frequency or type of AE
resulting in discontinuation.
Discussion
In BENEFIT-ALS, a large, 12-week, randomized,
placebo-controlled, double-blind phase IIb study,
tirasemtiv was observed to statistically significantly
reduce the slope and magnitude of SVC decline
compared with placebo (15). Significant effects on
the change from baseline in SVC were also observed
at all tirasemtiv doses reached (total daily dose of
250mg, 375mg, or 500mg) (17). Additionally, the
results from BENEFIT-ALS demonstrated that the
riluzole exposure, as measured by area under the
curve, was approximately the same in participants
administered with any daily dose of tirasemtiv along
with half the labeled riluzole dose (i.e. 50mg/day)
compared to the participants who were randomized
to placebo and taking the recommended labeled
riluzole dose of 100mg/day (17). Tirasemtiv was
Table 3. Baseline characteristics: open-label phase.
Demographica Non-riluzole n¼ 191 Riluzole n¼ 553 All n¼ 744
Age, years 58.510.6 57.3 10.2 57.6 10.3
Sex, male, n (%) 126 (66.0) 359 (64.9) 485 (65.2)
BMI, kg/m2 27.23.8 26.8 4.3 26.9 4.2
Weight, kg 80.615.1 79.0 15.6 79.4 15.5
Months from diagnosis 7.06.1 7.9 5.7 7.7 5.8
Months from first symptom 22.318.5 20.1 11.7 20.6 13.8
ALSFRS-R 37.95.5 38.2 5.0 38.1 5.1
SVC, % predicted 91.715.5 90.3 15.8 90.7 15.7
ALSFRS-R: ALS Functional Rating Scale-Revised; BMI: body mass index; SVC: slow vital capacity.
aMean standard deviation unless otherwise indicated.
Table 4. Participants with AEs: open-label phasea.
Preferred term, n (%) Non-riluzole n¼ 191 Riluzole n¼ 553 All n¼ 744
Participants with any AE 165 (86.4) 448 (81.0) 613 (82.4)
Dizziness 93 (48.7) 237 (42.9) 330 (44.4)
Fatigue 57 (29.8) 136 (24.6) 193 (25.9)
Nausea 35 (18.3) 71 (12.8) 106 (14.2)
Somnolence 23 (12.0) 63 (11.4) 86 (11.6)
Muscular weakness 11 (5.8) 36 (6.5) 47 (6.3)
Decreased appetite 12 (6.3) 30 (5.4) 42 (5.6)
AE: adverse event.
aFrequency45%.
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noted to reduce SVC decline regardless of whether
the participant was taking riluzole or not and
regardless of other disease baseline characteristics
(17). Overall, the relationship between the plasma
concentration and dose of tirasemtiv and its effects
on SVC suggested that lower target doses of
tirasemtiv than studied in BENEFIT-ALS may
warrant further evaluation (17), although any such
conclusions are tentative based on the fact that
participants were not randomized to different doses
in that study.
The VITALITY-ALS study was designed to
build on the findings from BENEFIT-ALS and to
further evaluate and to confirm the efficacy of
tirasemtiv as a treatment for patients with ALS. The
design of VITALITY-ALS addresses tolerability
issues by increasing the open-label lead-in from
one to two weeks and by including a slower (every
two weeks vs. every week) dose titration (18) in
participants randomized to tirasemtiv target dose
levels above 250mg/day. Participants were rando-
mized to specific target dose levels (allowing for
down titration) which is a different dosing strategy
than taken in BENEFIT-ALS where the goal was to
reach each patient’s maximum tolerated dose up to a
maximum total daily dose of 500mg. Randomizing
to specific target dose levels in VITALITY-ALS
would help better understand the relationship
between each dosing strategy and the effect of
tirasemtiv on SVC (18).
As tirasemtiv was observed to significantly
reduce SVC slope previously (15), the primary
endpoint in VITALITY-ALS was change in percent
predicted SVC from baseline to week 24 in the
double-blind, placebo-controlled phase. Key sec-
ondary endpoints included assessing the effect of
tirasemtiv on muscle strength, the respiratory
domain of the ALSFRS-R, and time to certain
respiratory milestones of disease progression, such
as the initiation of assisted ventilation. In addition,
the increase from 12 to 48 weeks allows for a longer
evaluation of participants with the ALSFRS-R, the
measure used as the primary endpoint at 12 weeks
in the BENEFIT-ALS study (Supplemental
Figure 1).
Initial results from VITALITY-ALS indicate that
the most commonly reported AEs were dizziness,
fatigue, and nausea and were the most common
reasons for study discontinuation similar to the
open-label phase of BENEFIT-ALS; although diz-
ziness, fatigue, and nausea were reported at higher
percentages and discontinuation due to these AEs
was also higher in VITALITY-ALS compared with
BENEFIT-ALS (open-label discontinuation rates of
Table 5. Serious AEs: open-label phase.
Preferred term, n (%) Non-riluzole n¼191 Riluzole n¼553 All n¼ 744
Participants with serious AE 3 (1.6) 7 (1.3) 10 (1.3)
Serious AEs
Appendicitis 1 (0.5) 0 1 (0.1)
Confusional state 0 1 (0.2) 1 (0.1)
Deep vein thrombosis 0 1 (0.2) 1 (0.1)
Dyspnea 0 1 (0.2) 1 (0.1)
Ileus 1 (0.5) 0 1 (0.1)
Lobar pneumonia 0 1 (0.2) 1 (0.1)
Mania 0 1 (0.2) 1 (0.1)
Nausea 1 (0.5) 0 1 (0.1)
Pneumonia aspiration 0 1 (0.2) 1 (0.1)
Pulmonary embolism 0 1 (0.2) 1 (0.1)
Respiratory failure 1 (0.5) 0 1 (0.1)
Rib fracture 0 1 (0.2) 1 (0.1)
Urinary retention 1 (0.5) 0 1 (0.1)
AE: adverse event.
Table 6. Participant disposition.
Study phase Participantsa Non-riluzole (n¼ 191) Riluzole (n¼ 553) All (n¼ 744)
Open-label Total discontinued participants 50 (26.2) 129 (23.3) 179 (24.1)
Discontinued due to AEs 47 (24.6) 125 (22.6) 172 (23.1)
Discontinued due to consent withdrawn 1 (0.5) 1 (0.2) 2 (0.3)
Discontinued due to protocol violation 0 2 (0.4) 2 (0.3)
Discontinued due to other 1 (0.5) 0 1 (0.1)
Unknown as of data cutoff 1 (0.5) 1 (0.2) 2 (0.3)
Double-blind Number of randomized participantsb 141 424 565
AE: adverse event.
aNumber (%) unless otherwise indicated.
bOne participant was randomized but did not take any double-blind dose. Last dose for this participant was prior to the randomization date
and early termination was due to an AE.
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24.1% and 16.2%, respectively). These initial
findings suggest the strategy of using a longer lead-
in period in VITALITY-ALS was effective in better
selecting participants who would tolerate active
treatment during the randomized phase of the trial.
In conclusion, VITALITY-ALS incorporated
findings from the BENEFIT-ALS trial and extended
the period of active treatment to demonstrate a
sustained effect of tirasemtiv in patients with ALS.
VITALITY-ALS evaluated the hypotheses that
tirasemtiv significantly reduces SVC decline over
24 weeks vs. placebo and has a clinically meaningful
impact on other respiratory measures over a 48-
week time span. Study completion is expected in the
fourth quarter of 2017.
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